Bausch + Lomb(NYSE) BLCO

Bausch + Lomb helps people see more clearly by making contact lenses, surgical tools, and eye medicines. These products treat common issues like dry eyes, cataracts, and blurry vision for patients of all ages. The company sells its goods to eye doctors, hospitals, and shoppers in stores around the world.

What Is in the Catalog?

• Vision Care: Contact lenses and eye vitamins like PreserVision; accounted for 57% of revenue in 2025.
• Pharmaceuticals: Prescription drops for glaucoma and dry eye, including Xiidra and Miebo; made up 25% of revenue in 2025.
• Surgical: Equipment and lenses used during eye surgeries to replace cloudy natural lenses; contributed 18% of revenue in 2025.
• Consumer Eye Care: Over-the-counter solutions for lens cleaning and allergy relief like Biotrue and Lumify.

Recent Strategic Moves

• Acquired Xiidra in the third quarter of 2023 to expand the dry eye treatment portfolio.
• Launched the Miebo eye drop in the United States in September 2023.
• Introduced enVista Envy trifocal lenses in Canada in June 2024 and the United States in November 2024.
• Secured an exclusive license from Novaliq GmbH for the development of eye treatments in the U.S. and Canada.

A Global Eye Health Network

The company maintains a significant global footprint with approximately 13,000 employees and a presence in 100 countries. It operates 13 research and development facilities to manage a pipeline of over 60 active projects across different therapeutic areas.

The Latest Financial Facts

• Revenue reached $1.4 billion in Q4 2025, up 9.8% from the previous year.
• Operating income rose to $158 million in Q4 2025, an 81.6% increase year-over-year.
• Free cash flow turned positive at $61.8 million in Q4 2025, up 188.3% from a loss in Q4 2024.
• Operating cash flow grew to $134.3 million in Q4 2025, up 510.6% from the prior year.

The Evolution of Bausch + Lomb

Founded in 1853, the company has transformed from a local business into a global eye health specialist. It recently transitioned into an independent public entity following its 2022 initial public offering while maintaining a broad portfolio of nearly 400 products.